Aplastic anemia (AA)

  • Method:
  • Anticoagulant:
  • Recommendation:
  • Method:
    Cytomorphology
  • Anticoagulant:
    EDTA
  • Recommendation:
    obligatory
  • Method:
    Immunophenotyping
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    facultative
  • Method:
    Chromosome analysis
  • Anticoagulant:
    Heparin
  • Recommendation:
    obligatory
  • Method:
    FISH
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    facultative
  • Method:
    Molecular genetics
  • Anticoagulant:
    EDTA or Heparin
  • Recommendation:
    obligatory

Acquired aplastic anemias (AA) are characterized by bi- or tricytopenias resulting from hypo- or aplasia in the bone marrow. The annual incidence of the disease in Central Europe is 2-3:1,000,000. Aplastic anemias can occur at any age, with a first peak in patients between 10 and 25 years of age and a second peak in patients over 60 years of age (Marsh et al. 2003, Marsh et al. 2009, Killick et al. 2016).

Characteristics of aplastic anemia

Patients with aplastic anemia typically initially experience benign oligoclonal hematopoiesis due to a reduction in the stem cell pool as a result of immune-mediated pathogenesis, in which autoreactive T cells appear to play a major role (Marsh et al. 2009, Ogawa 2016). During the pathogenesis of aplastic anemia, the majority of bone marrow cells are replaced by adipocytes (Young 2018). In contrast, MDS are hematopoietic stem cell disorders with monoclonal hematopoiesis displacing normal polyclonal hematopoiesis (Afable et al. 2011).

To diagnose aplastic anemia, exclusion of other causes is essential. These include acquired cytopenias, for example, viral or drug-induced, as well as congenital syndromes with bone marrow insufficiency or hypoplastic myelodysplastic syndrome (MDS) (Marsh et al. 2003, Marsh et al. 2009, Killick et al. 2016). Diagnostics should allow for such exclusion and therefore include cytomorphology, histology, and cytogenetics from bone marrow in all cases.

Classification of aplastic anemia

Aplastic anemia can be classified into different severity levels, which are listed in Table 1:

Table 1: Classification of aplastic anemia (two of three criteria must be met)

(Onkopedia Leitlinie AA 2018).


Non-severe AASevere AAVery severe AA
Neutrophil count< 1.0 G/L
< 0.5 G/L
< 0.2 G/L
Platelets< 50 G/L
< 20 G/L< 20 G/L
Reticulocyte count< 20 G/L
< 20 G/L< 20 G/L


To diagnose very severe aplastic anemia, < 0.2 G/L neutrophil granulocytes  and hypocellular bone marrow must be present (cellularity < 25% or 25-50% with < 30% hematopoietic cells in the bone marrow), whereas evidence of hypocellular bone marrow is sufficient to diagnose non-severe aplastic anemia (Onkopedia guideline AA 2018).

Diagnostics of aplastic anemia

Aplastic anemia: Prognosis

Good prognosis in trisomy 8 and 13q deletions

Patients with trisomy 8 show a better response to immunosuppressive therapy, a lower leukemic transformation rate, and better overall survival than patients with abnormalities on chromosome 7. This alteration is associated with a poor response to immunosuppressive therapy, persistent pancytopenia, and an adverse prognosis. Deletions in the long arm of a chromosome 13 (13q deletion), like trisomy 8, are associated with more stable blood counts and a good response to immunosuppressive therapy (Ishiyama et al. 2002, Maciejewski et al. 2002, Maciejewski & Selleri 2004, Kim et al. 2010).


Genetic alterations influence transformation rate and response to therapy

The risk of leukemic transformation is significantly increased when cytogenetic alterations are detected in chromosome banding analysis (see Fig. 1).

Figure 1: Cumulative probability of leukemic transformation within 5 years in aplastic anemia with normal versus aberrant karyotype (created after Kim et al. 2010).

Response to immunosuppressive therapy may be worse (-7, complex karyotype, 5q syndrome) or better (+8, -13q) depending on the type of cytogenetic alteration (Maciejewski & Selleri 2004, Kim et al. 2010).

Clonal evolution to MDS occurs in up to 25% of patients with aplastic anemia within a 10-year period. Whether clonal evolution is a late complication in the pathogenesis of aplastic anemia or whether occurring myelodysplastic syndromes are related to immunosuppressive therapy remains unclear to date (Maciejewski & Selleri 2004, Afable et al. 2011).

In addition to cytogenetic alterations, molecular aberrations such as mutations of the ASXL1 and DNMT3A genes may also increase the risk of developing MDS or AML (see Molecular genetics) (Kulasekararaj et al. 2014).

Aplastic anemia: Therapy

With the help of immunosuppressive therapies (IST), approximately 50% of patients with aplastic anemia achieve remission, with significantly higher response in patients with age ≤ 67 years (p=0.002), coexistence of a PNH clone (p=0.017), and normal karyotype (p=0.024) (Maciejewski & Selleri 2004, Kim et al. 2010). Patients with mutations of the PIGA, BCOR and BCORL1 genes also respond significantly better to IST (Yoshizato et al. 2015, Ogawa 2016).

Aplastic anemia: Recommendation

Differentiation from MDS important for prognosis

Differentiation of aplastic anemia from hypoplastic MDS is important for prognosis assessment as well as for the choice of therapeutic strategies despite the partially overlapping symptoms (see also Fig. 2), but morphologic analyses are challenging because of the cell-poor bone marrow.

Fig. 2: Overview of common symptoms in aplastic anemia and hypoplastic MDS (modeled after Mufti et al. 2018).

Therefore, histological examination on a sufficiently large bone marrow cylinder (at least 15 mm biopsy length) should definitely be performed to establish the diagnosis. Indications of clonal evolution in the course of aplastic anemia are an increased blast percentage, hypercellular bone marrow in the presence of recurrent or persistent cytopenia, and the appearance of new cytogenetic or molecular genetic abnormalities (Maciejewski & Selleri 2004, Afable et al. 2011).

Other differential diagnoses include clonal cytopenia of undetermined significance (CCUS) and paroxysmal nocturnal hemoglobinuria (PNH). In CCUS, the bone marrow is hypo- to hypercellular, and somatic mutations are more frequent than in aplastic anemia , particularly affecting the genes TET2, DNMT3A, ASXL1, TP53, and splicing factors, among others; therefore, molecular genetic analyses could also aid diagnosis in this case. Aplastic anemia and PNH can each develop into each other (AA/PNH syndrome). Major clues for the presence of PNH or a PNH clone are CD59-negative cells in immunophenotyping and mutations of the PIGA gene (Ogawa 2016, Bejar 2020).

Because patients with somatic mutations are at higher risk of developing MDS, early molecular genetic diagnosis may be informative. This is also supported by the improved response to IST in mutations of the PIGA, BCOR, and BCORL1 genes, which may contribute to treatment decisions (Kulasekararaj et al. 2014, Yoshizato et al. 2015).

You may also be interested in

Career

As a rapidly growing, innovative medical laboratory, we are always looking for bright minds to help us bring new and more effective therapies to patients around the world.

Learn more

Services

Do you have questions about sample submission, analyses performed or findings? Here you will find contact details, contact persons and our most frequently asked questions (FAQs).

Learn more

Quality management

We have been certified according to national and international standards since 2009 and have successfully maintained these accreditations.

Learn more